TY - JOUR
T1 - Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0)
AU - Japanese Society of Medical Oncology
AU - Japan Society of Clinical Oncology
AU - Japanese Cancer Association
AU - Sunami, Kuniko
AU - Takahashi, Hideaki
AU - Tsuchihara, Katsuya
AU - Takeda, Masayuki
AU - Suzuki, Tatsuya
AU - Naito, Yoichi
AU - Sakai, Kazuko
AU - Dosaka-Akita, Hirotoshi
AU - Ishioka, Chikashi
AU - Kodera, Yasuhiro
AU - Muto, Manabu
AU - Wakai, Toshifumi
AU - Yamazaki, Kentaro
AU - Yasui, Wataru
AU - Bando, Hideaki
AU - Fujimoto, Yumi
AU - Fukuoka, Shota
AU - Harano, Kenichi
AU - Kawazoe, Akihito
AU - Kimura, Gen
AU - Koganemaru, Shigehiro
AU - Kogawa, Takahiro
AU - Kotani, Daisuke
AU - Kuboki, Yasutoshi
AU - Matsumoto, Hiroshi
AU - Matsumoto, Shingo
AU - Mishima, Saori
AU - Nakamura, Yoshiaki
AU - Sawada, Kentaro
AU - Shingaki, Sumito
AU - Shitara, Kohei
AU - Umemoto, Kumiko
AU - Umemura, Shigeki
AU - Yasuda, Kayo
AU - Yoshino, Takayuki
AU - Yamamoto, Noboru
AU - Nishio, Kazuto
N1 - Funding Information:
This work was supported by the Japanese Society of Medical Oncology (JSMO), the Japan Society of Clinical Oncology (JSCO), and the Japanese Cancer Association (JCA). The JSMO and JSCO, and JCA Guideline Committee members reviewed the guidance. This project was supported by Health Labour Sciences Special Research Grant (H30-17).
Publisher Copyright:
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2018/9
Y1 - 2018/9
N2 - In Japan, the social (medical) health-care system is on the way to being developed to advance personalized medicine through the implementation of cancer genomic medicine, known as “cancer clinical sequencing,” which uses a next-generation sequencer. However, no Japanese guidance for cancer genomic testing exists. Gene panel testing can be carried out to help determine patient treatment, confirm diagnosis, and evaluate prognostic predictions of patients with mainly solid cancers for whom no standard treatment is available. This guidance describes how to utilize gene panel testing according to the type of cancer: childhood cancer, rare cancer, carcinoma of unknown primary, and other cancers. The level of evidence classification for unified use in Japan is also detailed. This guidance establishes the basic principles of the quality control of specimens, requirements of medical institutions, informed consent, handling of data during the postanalysis stage, and treatment options based on the evidence level. In Japan, gene panel testing for cancer treatment and diagnosis is recommended to comply with this guidance. This is a collaborative work of the Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, and the Japanese Cancer Association.
AB - In Japan, the social (medical) health-care system is on the way to being developed to advance personalized medicine through the implementation of cancer genomic medicine, known as “cancer clinical sequencing,” which uses a next-generation sequencer. However, no Japanese guidance for cancer genomic testing exists. Gene panel testing can be carried out to help determine patient treatment, confirm diagnosis, and evaluate prognostic predictions of patients with mainly solid cancers for whom no standard treatment is available. This guidance describes how to utilize gene panel testing according to the type of cancer: childhood cancer, rare cancer, carcinoma of unknown primary, and other cancers. The level of evidence classification for unified use in Japan is also detailed. This guidance establishes the basic principles of the quality control of specimens, requirements of medical institutions, informed consent, handling of data during the postanalysis stage, and treatment options based on the evidence level. In Japan, gene panel testing for cancer treatment and diagnosis is recommended to comply with this guidance. This is a collaborative work of the Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, and the Japanese Cancer Association.
KW - evidence level
KW - gene panel testing
KW - guidance
KW - next-generation sequencing
KW - solid cancer
UR - http://www.scopus.com/inward/record.url?scp=85052807644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052807644&partnerID=8YFLogxK
U2 - 10.1111/cas.13730
DO - 10.1111/cas.13730
M3 - Article
C2 - 30187675
AN - SCOPUS:85052807644
VL - 109
SP - 2980
EP - 2985
JO - Cancer Science
JF - Cancer Science
SN - 1347-9032
IS - 9
ER -